Shire Says Investors More Favorable Now To Baxalta Bid
This article was originally published in Scrip
Executive Summary
Shire PLC's large investors are more on board with the firm's pursuit of Baxalta Inc. than they were when the bid first was announced in August, and the specialty pharma says it will continue to seek a merger that would create a rare disease powerhouse with 30 new products and $20bn in annual revenue by 2020.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine
Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.
Viking’s Oral Weight-Loss Drug Shows Early Efficacy/Safety Promise
An oral formulation of the GLP-1/GIP analog VK2735 showed up to 5.3% reduction in body weight after four weeks in a Phase I study, with a nearly pristine safety and tolerability profile.